PIK3CA and urinary bladder carcinoma: Tamura et al. examined how HER2 and HER3 mutations conveyed sensitivity to the targeted therapies dacomitinib (PIK3CA) and afatinib, an irreversible HER family inhibitor, in bladder cancer via in vitro methods [46].